133 related articles for article (PubMed ID: 9710365)
1. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance.
Laube H; Linn T; Heyen P
Exp Clin Endocrinol Diabetes; 1998; 106(3):231-3. PubMed ID: 9710365
[TBL] [Abstract][Full Text] [Related]
2. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.
Inoue I; Takahashi K; Noji S; Awata T; Negishi K; Katayama S
Diabetes Res Clin Pract; 1997 Jun; 36(3):143-51. PubMed ID: 9237780
[TBL] [Abstract][Full Text] [Related]
3. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Chiasson JL; Josse RG; Leiter LA; Mihic M; Nathan DM; Palmason C; Cohen RM; Wolever TM
Diabetes Care; 1996 Nov; 19(11):1190-3. PubMed ID: 8908378
[TBL] [Abstract][Full Text] [Related]
4. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
[TBL] [Abstract][Full Text] [Related]
5. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Chiasson JL
Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
[TBL] [Abstract][Full Text] [Related]
6. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
[TBL] [Abstract][Full Text] [Related]
7. The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study.
Rachmani R; Bar-Dayan Y; Ronen Z; Levi Z; Slavachevsky I; Ravid M
Diabetes Obes Metab; 2004 Jan; 6(1):63-8. PubMed ID: 14686965
[TBL] [Abstract][Full Text] [Related]
8. Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?
Scott R; Lintott CJ; Zimmet P; Campbell L; Bowen K; Welborn T
Diabetes Res Clin Pract; 1999 Mar; 43(3):179-85. PubMed ID: 10369427
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB
Arch Intern Med; 1994 Nov; 154(21):2442-8. PubMed ID: 7979840
[TBL] [Abstract][Full Text] [Related]
10. Effect of acarbose on glucose intolerance in patients with non-insulin-dependent diabetes mellitus.
Noda K; Umeda F; Nawata H
Diabetes Res Clin Pract; 1997 Aug; 37(2):129-36. PubMed ID: 9279483
[TBL] [Abstract][Full Text] [Related]
11. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients.
Fischer S; Patzak A; Rietzsch H; Schwanebeck U; Köhler C; Wildbrett J; Fuecker K; Temelkova-Kurktschiev T; Hanefeld M
Diabetes Obes Metab; 2003 Jan; 5(1):38-44. PubMed ID: 12542723
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
[TBL] [Abstract][Full Text] [Related]
13. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
Hoffmann J; Spengler M
Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
[TBL] [Abstract][Full Text] [Related]
15. Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity.
Jenney A; Proietto J; O'Dea K; Nankervis A; Traianedes K; D'Embden H
Diabetes Care; 1993 Feb; 16(2):499-502. PubMed ID: 8432223
[TBL] [Abstract][Full Text] [Related]
16. Treatment of poorly controlled non-insulin-dependent diabetic patients with Acarbose.
Scott RS; Knowles RL; Beaven DW
Aust N Z J Med; 1984 Oct; 14(5):649-54. PubMed ID: 6397178
[TBL] [Abstract][Full Text] [Related]
17. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
[TBL] [Abstract][Full Text] [Related]
18. A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch acarbose intervention study in persons with impaired glucose tolerance (DAISI).
Nijpels G; Boorsma W; Dekker JM; Kostense PJ; Bouter LM; Heine RJ
Diabetes Metab Res Rev; 2008; 24(8):611-6. PubMed ID: 18756586
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Fogari E; Salvadeo SA; Ferrari I; Gravina A; Fassi R; Fogari R
Clin Drug Investig; 2006; 26(9):529-39. PubMed ID: 17163286
[TBL] [Abstract][Full Text] [Related]
20. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB; Bray GA
Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
